Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.49USD
25 May 2018
Change (% chg)

$-0.03 (-1.19%)
Prev Close
$2.52
Open
$2.51
Day's High
$2.51
Day's Low
$2.46
Volume
18,620
Avg. Vol
30,842
52-wk High
$6.06
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $44.83
Shares Outstanding(Mil.): 17.74
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -2.06 -- --
ROI: -65.38 -7.30 12.79
ROE: -135.04 -10.05 14.67

BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol

* PHASE III CLINICAL STUDY OF THERMODOX IN COMBINATION WITH RADIOFREQUENCY ABLATION TO CONTINUE ACCORDING TO PROTOCOL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 09 2018

BRIEF-Celsion Corporation Provides Corporate Update And 2018 Outlook

* CELSION CORPORATION PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK

Jan 18 2018

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

Jan 04 2018

Earnings vs. Estimates